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Deconvoluting key biological mechanisms forms the framework for therapeutic discovery.
Strategies that enable effective translation of those insights along the development and
regulatory path, ultimately, drive validated clinical application in patients and populations.
Accordingly, parity in What versus How we transform novel mechanistic insights into
therapeutic paradigms is essential in achieving success. Aligning molecular discovery with
innovations in structures and processes along the Discovery-Development-RegulationUtilization continuum maximizes the return on public and private investments for next
generation solutions in managing health and disease.
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The whole is greater than the sum of its parts.
Aristotle
When considering therapeutic innovation, we naturally focus on biological discovery and the
associated advances in technology, which have revolutionized clinical management paradigms
and the delivery of care to patients and populations.1 This evolution reflects the exponential
growth in bio-innovation propelled by public-private partnership investment in generating
platforms for solutions to health and disease that benefit communities, now and in the future.2
This scientific revolution drives the development of increasingly precise solutions, leveraging
insights in molecular mechanisms within a systems context underlying pathophysiology which
offer biologically-based targets for novel therapies, enhance the ability to find cures, and
restrict adverse events.3 Indeed, the increasing toolbox of cutting-edge platforms has produced
unprecedented opportunities to individualize and indeed optimize drugs, devices, and their
delivery, that can be best aligned across the spectrum of diseases, communities, and
geographies to reach global populations in need.1 The biotechnology and pharmaceutical
industry, in turn, has translated these biological advances into new preventive, diagnostic, and
treatment approaches that are evolving health and the care of patients and their diseases in
ways that were only imagined a decade earlier.2 The developing framework established by
biologically targeted biomarker, device, and therapeutic paradigms alters the one-size-fits-all
method to managing patients into individualized health solutions.4 These developments are
poised to advance, and that acceleration is reflected in emerging fields like regenerative
medicine which is poised to drive the management of degenerative diseases and wellness
through direct manipulation of innate regenerative reserves for tissue and organ renewal.5
3

In every chain of reasoning, the evidence of the last conclusion can be no greater than that of
the weakest link of the chain, whatever may be the strength of the rest.
Thomas Reid
Clearly, this revolution in biology and molecular discovery is the engine of disruptive innovation
that ultimately propels the development of novel paradigms to maintain health and treat
disease. However, regardless of the strength of that engine of invention, clinical translation of
basic innovation can only advance at the rate of the slowest component of the DiscoveryDevelopment-Regulation-Utilization (DDRU) continuum.2 Translation and ultimately adoption
into the clinic can only be accelerated if we begin to streamline clinical trial processes.6 Greater
rates of success in clinical development will be achieved by innovation in the development of
biomarkers that can predict responses, outcomes, and adverse events that advantage novel
clinical trial designs.7, 8 Regulatory decisions about relative value of developing therapeutics will
reflect new paradigms in assessing relative risk and benefit.9-11 Increased access to expensive
biological medicines, whose associated prices are unsustainable for healthcare systems with
finite resources, will be achieved through novel regulatory pathways encouraging the
availability of biosimilars.12 Ultimately, innovation in the components of the processes that
translate novel molecular discoveries into cutting-edge therapies are as important, if not more
so, than the molecular targets being translated.2
These considerations are underscored by considering the emerging field of regenerative
medicine, which is revolutionizing all aspects of therapeutic disease management, with a
particular focus on degenerative diseases.13 The paradigm suggests that we can improve the
endogenous regenerative capacities of tissues that undergo disruption because of injury,
4

disease or chronic insult by stimulating tissue-specific regeneration, and/or amplifying
endogenous repair propensity.14 For example, articular cartilage damage ultimately progresses
to end-stage osteoarthritis, affecting about a million people in the U.S.15 In that context,
autologous chondrocyte implantation (ACI) regimens have become standard-of-care in
specialized orthopedic clinics focused on osteoarthritis.15 Similarly, myocardial damage from
ischemic heart disease has produced an explosion in chronic heart failure with its associated
morbidities and mortality. This is another example in which regenerative approaches through
the provision of stem cells instructed to repair the damaged myocardium and restore cardiac
function is potentially revolutionizing the management of heart failure.13, 14, 16-18 However, while
these technological approaches are poised to transform the outcomes of debilitating and
deadly conditions, their penetration to the management of patients and populations is
hindered by regulatory structures and regulations which have not kept pace. Indeed, there is
marked variation in marketing, clinical practice guidelines, local and central regulation, as well
as reimbursement policies across national jurisdictions.19 In that context, the majority of
research and development activities in this field are still undertaken locally by academic
developers and small and medium-sized enterprises.19,

20

These consideration highlight the

need for improved coordination across medical and regulatory communities.19,

20

Moreover,

there is a need to build platforms for knowledge sharing, collaboration and learning among
academia, developers and regulatory authorities.19 New models of pre-competitive
collaboration should be utilized to increase research efficiencies while collaborations between
regulatory agencies and interactions with developers need to be strengthened and
harmonized.19, 20 The importance of these issues can best be appreciated by considering that
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the FDA has declared these opportunities for innovation a key priority to advance regenerative
therapies into patients and populaitons.21
Similarly, biomarkers have transformed health care management paradigms across a broad
spectrum of diseases.3 These include biomarkers that forecast who will develop a disease, those
that prognose whose disease will advance, and those that predict who will respond to therapy. 8
Nowhere is the impact of biomarkers more apparent than in the management of patients with
cancer.22,

23

In that context, biomarkers can segment the population of patients with a

particular type of cancer into the precise mutations that underlie their specific disease,
providing a mechanistic target that, in many cases, is sensitive to an emerging biologicallydirected therapy.24 These biomarker-driven approaches to molecularly segmenting tumors by
mutational identity is revolutionizing the development of novel biological therapies and the
associated transformation of clinical trials paradigms to accelerate their approval and
availability to patients that need them.24,

25

In turn, this acceleration of discovery and

development is reciprocally driving biomarker innovation, to identify more sensitive and
specific diagnostic paradigms for predicting therapeutic results and eliminating adverse events
of novel therapeutics.8, 26 Development of the paradigm for model-informed proarrhythmic risk
assessment of drugs is an example of innovation in the design of biomarker paradigms that
minimize the risk of adverse events.27 In addition, the rapid evolution of targeted therapies in
oncology, many of which are toxic, has entrained the regulatory sciences to match that
innovation with novel paradigms that quantify the relative benefit and risk of new therapies, to
enable only compounds with the most favorable therapeutic and safety profiles to be approved
for patients.11, 26, 28 Beyond the classical biomarkers encompassing cell and molecular analytes,
6

emerging technologies encompassing wearable biosensors with their ability to actuate real time
reporting of basic pathophysiological metrics are poised to transform the field by monitoring
the therapeutic and adverse effects of novel agents.11, 26, 28 It is noteworthy that while the pace
of biomarker development is accelerating, there remain gaps in commercial incentives that
drive biomarker innovation.29 Moreover the growing dependence of clinical drug development
programs on biomarkers has created previously unanticipated challenges in ethical frameworks
surrounding human clinical trials.7
Bench-to-bedside translation continues to drive innovation across the DDRU continuum. Case in
point, deconvolution of the contribution of the IL-23/TH17 molecular pathways to
inflammatory diseases has revealed pathophysiological processes common to a variety of
autoimmune-mediated conditions.30 Indeed, the recognition of IL-23 and IL-17 as key cytokines
in promoting inflammation and tissue destruction has led to the development of several
biologic agents.30 In turn, these mechanistic insights have been translated into unprecedented
therapeutic achievements for conditions including psoriasis, psoriatic arthritis, and rheumatoid
arthritis.30 However, it is noteworthy that these agents, in the class of biologics, generally have
been burdened by high costs which are unsustainable for health care systems with limited
resources.2 In that context, innovations in the regulatory sciences established the biosimilars
program of the European Medicines Agency (EMA) and, more recently, the FDA which provide
pathways for the development of economic generic alternatives once the patent life of
innovator products has elapsed.12, 31 In turn, these programs maximize opportunities for access
to those important agents by the broadest populations of the neediest patients.31
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In the context of the burgeoning opioid crisis, neonatal abstinence syndrome has become a
major problem for babies born to addicted mothers.32 Buprenorphine has demonstrated an
efficacy advantage over standard opioid replacement therapy for the neonatal abstinence
syndrome in both controlled clinical trials and treatment settings.32 Buprenorphine is safe in the
neonatal abstinence syndrome, and sublingual dosing has been demonstrated to be feasible in
the neonatal population.33 Indeed the use of sublingual buprenorphine resulted in a reduction
in the median duration of treatment, median length of stay, and requirement for adjunctive
therapies compared to oral morphine.33 It is noteworthy that the total number of treated
patients in these cohorts is modest, although the consistency in effect size in different
populations provides external validity to the findings.32, 33 However, these types of studies, in
which cohorts of patients available to individual investigators are modest, can be remarkably
accelerated in the future by building public-private partnerships across heterologous platforms
to share data, patients, and approaches through digital technologies.34, 35
Advances in the development of prevention, detection, and treatment of diseases have
amplified beyond the limits of our past concepts of canonical small molecule therapeutics,
reflecting emerging insights into molecular mechanisms and biological targets.2-4 While success
in discovery innovation has been dramatic, the translation of those laboratory-based inventions
into effective therapies for individual patients and scalable for populations has been hindered
by a lag in parallel improvements in supporting structures along the DDRU continuum. 2
Emerging process improvements along this continuum should maximize the impact of discovery
innovations by facilitating their translation into novel therapeutic paradigms to maintain health,
and prevent and cure disease.
8
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